학술논문
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
Document Type
Article
Author
Source
In Annals of Oncology October 2021 32(10):1276-1285
Subject
Language
ISSN
0923-7534